Drugs / MTX101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06324604 | Jun 2024 → Mar 2027 expected | type 1 diabetes mellitus | Mozart Therapeutics Australia Pty Ltd | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06728553 | Feb → Jun 2025 | migraine disorder | Manistee Therapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MTX-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06324604 ↗ |
| Route | Intravenous | “MTX-101, Dose level 1 IV or Placebo IV” NCT06324604 ↗ |